The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

Lucia Mazzacurati(Molecular Oncology (United States)), Gary W. Reuther(Moffitt Cancer Center)
Oncotarget
October 12, 2015
10.18632/oncotarget.5653
Cited by 38

Related Papers

ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation
|PLoS ONE|2012|39
Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors
|Journal of Biological Chemistry|2010|30
<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms
|American Journal of Hematology|2024|4